SIX · ROP.SW
Roche Holding AG
CHF 403.40+CHF 1.70 (+0.42%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.62% below the high.
Loading market information…
SIX · BANB.SW · CHF
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 04:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CHF. Historical prices are not a forecast.
Bachem Holding AG’s quoted price sits in the upper half of its reported 52-week range, 2.27% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Bachem Holding AG’s forward annual dividend is CHF 0.90 per share, paid annual. The forward yield is 1.07% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Bachem Holding AG’s next earnings report is currently expected on Mar 4, 2027, with estimated earnings per share of CHF 1.58. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Bachem Holding AG’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
Latest available per-share figures in CHF. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 31, 2026, 01:23 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2023 | Mar 7, 2024 | CHF 0.39 | CHF 337.40M+5.34% vs estimate |
|---|
| Q2 2023 | Jul 27, 2023 | CHF 0.46-4.17% vs estimate | CHF 239.86M+4.3% vs estimate |
|---|
| Q4 2022 | Mar 7, 2023 | CHF 0.87-11.33% vs estimate | CHF 296.86M-2.3% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CHF 403.40+CHF 1.70 (+0.42%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.62% below the high.
CHF 133.78+CHF 1.48 (+1.12%)
Novartis AG’s quoted price sits in the upper half of its reported 52-week range, 0.95% below the high.
CHF 644.20+CHF 3.40 (+0.53%)
Lonza Group AG’s quoted price sits in the upper half of its reported 52-week range, 0.89% below the high.
CHF 192.85+CHF 3.15 (+1.66%)
Galderma Group AG’s quoted price sits in the upper half of its reported 52-week range, 0.54% below the high.
CHF 82.38-CHF 1.00 (-1.2%)
Sandoz Group AG’s quoted price sits in the upper half of its reported 52-week range, 3.78% below the high.
CHF 283.50+CHF 0.50 (+0.18%)
Dottikon ES Holding AG’s quoted price sits in the lower half of its reported 52-week range, 28.41% below the high.
CHF 71.80+CHF 1.00 (+1.41%)
Siegfried Holding AG’s quoted price sits in the lower half of its reported 52-week range, 29.33% below the high.
CHF 42.00-CHF 1.40 (-3.23%)
PolyPeptide Group AG’s quoted price sits in the upper half of its reported 52-week range, 16.17% below the high.
